PBSC mobilization for planned autologous transplantation fails in 5 --40% of cases.
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and 72% (156/217) 5 with G-CSF or G-CSF þ /ÀGM-CSF. Most recently, the CXCR4 inhibitor plerixafor combined with G-CSF has been found to successfully mobilize 70 --85% of patients failing previous mobilization 1 and 20/21 patients with advanced renal failure. 8 Less is known about risk factors for failure at second mobilization but these are of interest if novel and potentially costly mobilization strategies are to be used selectively.
We retrospectively examined records at NHSBT Leeds, West Yorkshire to identify all adult patients with haematological malignancy, who failed a PBSC mobilization (yield o2 Â 10 6
CD34
þ cells/kg) intended for auto-SCT and then proceeded to a second harvest attempt between 1999 and 2004. Data collected included number of lines and timing of preceding chemotherapy, age and renal function (serum creatinine normal or elevated) at time of re-harvest, harvest yield and engraftment data for patients subsequently transplanted. Statistical analysis was carried out using the 'R' package, R Development Core Team 2005 (R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0, URL http://www.R-project.org). Factors that might influence remobilization success were analysed in univariate analysis by odds ratios and then combined in a multivariate logistic regression model.
Overall, 36 patients were identified with a median age of 53.5 years (range 18 --67) at the time of remobilization. First prime was CY (1.5 --3 g/m 2 ) with G-CSF (5 --10 mg/kg/day) for 27, other chemotherapy (Table 1) with G-CSF (5 --10 mg/kg/day) for 7 and G-CSF (5 --10 mg/kg/day) alone for 2. Harvesting was not usually attempted if PBSC CD34 þ cell count was o10/mL. In all, 21 did not proceed to apheresis (19 due to PBSC CD34 þ cell count o10/mL, reason unknown for 2). A total of 15 achieved a median total harvest after first mobilization of 1.08 Â 10 6 CD34 þ cells/kg (range 0.4 --1.95) from a median of two apheresis procedures (range 1 --4). Bone
þ cell count o10/mL) and 20 achieved a median total harvest of 1.4 Â 10 6 CD34 þ cells/kg (range 0.36 --9.6) from a median of two apheresis procedures (range 1 --3). Two patients had prior radiotherapy and both successfully mobilized. All patients had at least one line of prior therapy containing a platinum compound, alkylating agent or purine analogue. No patient had received lenalidomide. The median gap between harvests was 10.5 weeks (range 2 --44 weeks) and median gap from last chemotherapy to second mobilization was 17.5 weeks (range 6 --84 weeks).
A total of 42% (15/36) patients mobilized sufficiently to achieve a total dose (first and second mobilization) X2 Â 10 6 CD34 þ cells/kg (median 2.8, range 2.0 --10.7). In univariate analysis, type of malignancy, age, gap from last chemotherapy and number of lines of prior chemotherapy did not predict outcome (Table 1 ). There was a trend towards successful mobilization if renal function was normal (P ¼ 0.056) or CY and G-CSF was the second mobilizing prime (0.053). However, in logistic regression, only renal function was an independent predictive factor (P ¼ 0.045). Initial mobilization p0.5 Â 10 6 CD34 þ cells/kg was highly predictive of failure to achieve an adequate total mobilization (P ¼ 0.001); however, this was excluded from logistic regression as the sum of both harvests will inevitably correlate with first harvest unless second harvest yield far exceeds that of the first harvest for all patients. Overall, 0/8 patients successfully mobilized if renal function was abnormal and initial harvest yield was p0.5 Â 10 6 CD34 þ cells/kg, 5/16 successfully mobilized where either was true and 10/12 successfully mobilized if renal function was normal and initial yield 40.5 Â 10 6 CD34 þ cells/kg. A total of 11 patients underwent transplantation. 0f 10 with adequate engraftment data, median time to neutrophil engraftment (40.5 Â 10 9 /L) was 15 days (range 12 --37) and platelet engraftment (X20 Â 10 9 /L) was 16 days (range 9 --61).
We confirm the inferiority of conventional remobilization with G-CSF þ /Àchemotherapy compared with recent data on plerixafor plus G-CSF. We also confirm that suboptimal first mobilization predicts poor outcome after second mobilization with cutoff values of 0.5 6 and 1.0 9 Â 10 6 CD34 þ cells/kg being discriminatory in other studies. Otherwise, risk factors for poor remobilization have not been consistently identified. Boeve et al. 7 found number of prior stem cell damaging regimens, higher white-cellcount at first mobilization and time from last chemotherapy to first mobilization to be significant in univariate but not multivariate analysis. In another study, univariate predictors of good outcome included better performance status, albumin, baseline platelet count and myeloma diagnosis, whereas time from last chemotherapy was not significant. 6 Increasing the gap between mobilization attempts does not appear beneficial. 5 Although myeloma patients with renal impairment can successfully mobilize with conventional agents, 10 we have identified renal impairment as a novel independent risk factor for poor remobilization. The number of patients with renal impairment (n ¼ 9) is a study limitation. A larger confirmatory study is justifiable, possibly defining renal impairment more precisely with estimated glomerular filtration rate (for example, o60 mL/min/1.73 m 2 ).
Although harvesting 2 Â 10 6 CD34 þ cells/kg is adequate for autografting, higher doses (for example, 5 Â 10 6 ) are optimal, with more rapid engraftment and fewer supportive measures. 1 As mobilization aims for the highest dose in the fewest apheresis sessions with the least toxicity, a strong case can be made for using effective agents such as plerixafor for all second mobilization attempts or at first mobilization in patients with risk factors for failure. If, however, financial restrictions require greater selectivity, patients with renal impairment or a first harvest yield o0.5 Â 10 6 CD34 þ cells/kg appear at greatest risk of failing second mobilization with conventional regimens.
